Search alternatives:
men decrease » nn decrease (Expand Search), we decrease (Expand Search), meja decreased (Expand Search)
nm decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
12 men » 10 men (Expand Search), 42 men (Expand Search)
men decrease » nn decrease (Expand Search), we decrease (Expand Search), meja decreased (Expand Search)
nm decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
12 men » 10 men (Expand Search), 42 men (Expand Search)
-
701
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
Published 2025Subjects: -
702
-
703
-
704
Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.
Published 2025Subjects: -
705
Baseline patient characteristics across neutralizing monoclonal antibody trials.
Published 2025Subjects: -
706
-
707
-
708
-
709
-
710
%-change after 3 and 12 months of hormone therapy in trans women and trans men.
Published 2022Subjects: -
711
Inflammation and hemostasis markers at 0, 3 and 12 months in trans men (absolute values).
Published 2022Subjects: -
712
-
713
-
714
-
715
-
716
-
717
Spatial information is significantly decreased in dCA1 and vCA1 in APP/PS1 mice.
Published 2024“…(B) In dCA1, spatial information was decreased in APP/PS1 mice relative to C57BL/6 controls (mean ± std: C57BL/6 = 0.132 ± 0.048, APP/PS1 = 0.128 ± 0.051, p < 0.005, two-sided Wilcoxon rank-sum test, n<sub>C57BL/6</sub> = 305 units from 5 recording sessions, n<sub>APP/PS1</sub> = 180 units from 4 recording sessions). …”
-
718
-
719
-
720
The prevalence of hypertension, diabetes, metabolic syndrome, cardiovascular disease and decreased GFR according to the following age groups: 60–69, 70–79 and ≥80 years.
Published 2017“…Diabetes mellitus: self-reported or a fasting plasma glucose ≥126 mg/dL or a glycohemoglobin ≥6.5%. …”